

# Jorge Eduardo Cortes

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6528350/jorge-eduardo-cortes-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

570  
papers

45,469  
citations

109  
h-index

195  
g-index

579  
ext. papers

52,094  
ext. citations

5.9  
avg, IF

7.19  
L-index

#	Paper	IF	Citations
570	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.. <i>Journal of Hematology and Oncology</i> , <b>2022</b> , 15, 1	22.4	2
569	Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.. <i>International Journal of Hematology</i> , <b>2022</b> , 1	2.3	0
568	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.. <i>Blood Reviews</i> , <b>2022</b> , 100968	11.1	2
567	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. <i>Haematologica</i> , <b>2021</b> , 106, 2853-2858	6.6	5
566	Knowledge of prostate cancer among African American men: A systematic review. <i>Prostate</i> , <b>2021</b> , 81, 202-213	4.2	3
565	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1181-1194	3	8
564	Third-line therapy for chronic myeloid leukemia: current status and future directions. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 44	22.4	12
563	Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 808-820	3.8	3
562	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , <b>2021</b> , 106, 2121-2130	6.6	10
561	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. <i>Cancer</i> , <b>2021</b> , 127, 2641-2647	6.4	5
560	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1000-1007	7.1	7
559	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 338-344	2	4
558	Health care access and utilization among adult cancer survivors: Results from the National Institutes of Health "All of Us" Research Program. <i>Cancer Medicine</i> , <b>2021</b> , 10, 3646-3654	4.8	2
557	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 94	22.4	5
556	Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , <b>2021</b> , 23, 91	6.3	3
555	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e481-e491	14.6	19
554	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 224-228	1.9	4

553	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 241-250	7.1	6
552	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 42-50	13.4	16
551	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 909-917	1.9	2
550	Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e497-e505	2.3	3
549	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , <b>2021</b> , 113, 92-99	2.3	7
548	Financial assistance programs for cancer patients <b>2021</b> , 3, 119-123		1
547	CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. <i>Hematologic Malignancies</i> , <b>2021</b> , 61-76	0	
546	Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 493-507	7.1	10
545	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , <b>2021</b> , 5, 1719-1728	7.8	8
544	Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 60	7	4
543	Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 110	22.4	2
542	The Care of the Leukemic Patients in Times of SARS-CoV-2. <i>Current Oncology Reports</i> , <b>2021</b> , 23, 114	6.3	0
541	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. <i>Blood</i> , <b>2021</b> , 138, 2042-2050	2.2	10
540	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , <b>2021</b> , 138, 2031-2041	2.2	23
539	Chronic myeloid leukaemia. <i>Lancet, The</i> , <b>2021</b> , 398, 1914-1926	40	6
538	Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 378-387	4.5	8
537	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias. <i>Leukemia Research</i> , <b>2021</b> , 111, 106690	2.7	2
536	Addressing financial toxicity in oncology care. <i>Journal of Hospital Management and Health Policy</i> , <b>2021</b> , 5,	0.5	4

535	Problems in living among breast cancer survivors <b>2021</b> , 3, 101-109		0
534	How to manage CML patients with comorbidities. <i>Hematology American Society of Hematology Education Program</i> , <b>2020</b> , 2020, 237-242	3.1	3
533	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, e871-e882	2	6
532	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. <i>Leukemia</i> , <b>2020</b> , 34, 2914-2924	10.7	2
531	The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1127	7.1	2
530	Long-term results of frontline dasatinib in chronic myeloid leukemia. <i>Cancer</i> , <b>2020</b> , 126, 1502-1511	6.4	12
529	Clinical value of event-free survival in acute myeloid leukemia. <i>Blood Advances</i> , <b>2020</b> , 4, 1690-1699	7.8	3
528	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. <i>Leukemia</i> , <b>2020</b> , 34, 2064-2073	10.7	10
527	Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. <i>Blood</i> , <b>2020</b> , 136, 41-42	2.2	12
526	Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. <i>Blood</i> , <b>2020</b> , 136, 47-50	2.2	13
525	Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. <i>Blood</i> , <b>2020</b> , 136, 51-52	2.2	8
524	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with $\geq$ Tyrosine Kinase Inhibitors (TKIs). <i>Blood</i> , <b>2020</b> , 136, 141-142	2.2	10
523	Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7502-7502	2.2	8
522	Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7509-7509	2.2	7
521	Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7512-7512	2.2	5
520	Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7525-7525	2.2	1
519	Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1574-1574	2.2	
518	Financial distress among breast cancer survivors <b>2020</b> , 2, 48-53		1

517	Optimizing management of acute leukemia in community centers and when to refer. <i>Hematology American Society of Hematology Education Program</i> , <b>2020</b> , 2020, 123-128	3.1	1
516	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 144-150	7.1	13
515	Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 631-640	1.9	7
514	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. <i>Nature Communications</i> , <b>2020</b> , 11, 5327	17.4	75
513	Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 137	22.4	7
512	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2811-2820	1.9	3
511	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 92	22.4	17
510	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1288-1295	7.1	10
509	How to manage CML patients with comorbidities. <i>Blood</i> , <b>2020</b> , 136, 2507-2512	2.2	6
508	Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1296-1303	7.1	7
507	A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. <i>Cancer</i> , <b>2020</b> , 126, 4315-4321	6.4	4
506	Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 3120-3127 <sup>1.9</sup>	1.9	5
505	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 451-459	3.5	3
504	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 3287-3305	1.9	2
503	Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , <b>2020</b> , 1, 134-145	7	15
502	Chronic Myeloid Leukemia <b>2020</b> , 1836-1849.e2		
501	Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 98-107	1.9	5
500	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , <b>2020</b> , 143, 567-573 <sup>2.7</sup>	2.7	24

499	Long-term results of a phase 2 trial of nilotinib 400mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. <i>Cancer</i> , <b>2020</b> , 126, 1448-1459	6.4	5
498	Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1728-1740	59.2	413
497	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 543-545	4.5	16
496	Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, S228-S229	2	3
495	Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, S231	2	4
494	Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. <i>Future Oncology</i> , <b>2019</b> , 15, 3531-3545	3.6	27
493	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 3172-3180	1.9	2
492	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 984-997	21.7	182
491	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 984-997	7.1	22
490	Hedgehog signaling inhibitors in solid and hematological cancers. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 76, 41-50	14.4	55
489	Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 509-515.e1 <sup>2</sup>		8
488	Improving attribution of adverse events in oncology clinical trials. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 76, 33-40	14.4	12
487	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , <b>2019</b> , 125, 2579-2586	6.4	35
486	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 1589-1599	4.9	11
485	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , <b>2019</b> , 109, 545-552	2.3	14
484	NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E158-E160	7.1	12
483	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2384-2393 <sup>1.9</sup>		4
482	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E188-E190	7.1	1



481	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. <i>Blood</i> , <b>2019</b> , 133, 2348-2351	2.2	33
480	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. <i>Haematologica</i> , <b>2019</b> , 104, 93-101	6.6	38
479	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. <i>Cancer</i> , <b>2019</b> , 125, 3755-3764	6.4	24
478	Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E256-E259	7.1	3
477	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1388-1395	7.1	13
476	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. <i>Cancer Medicine</i> , <b>2019</b> , 8, 6559-6565	4.8	11
475	Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2019</b> , 134, 382-382	2.2	2
474	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , <b>2019</b> , 134, 231-231	2.2	18
473	Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. <i>Blood</i> , <b>2019</b> , 134, 674-674	2.2	12
472	Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis. <i>Blood</i> , <b>2019</b> , 134, 2610-2610	2.2	1
471	PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I. <i>Blood</i> , <b>2019</b> , 134, 1638-1638	2.2	7
470	Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing B Prior TKI Therapies: Initial Safety and Efficacy. <i>Blood</i> , <b>2019</b> , 134, 4158-4158	2.2	7
469	Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7051-7051	2.2	1
468	Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18515-e18515	2.2	2
467	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. <i>Blood Advances</i> , <b>2019</b> , 3, 851-861	7.8	49
466	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. <i>Journal of Clinical Pharmacology</i> , <b>2019</b> , 60, 605	2.9	10
465	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2315-2326	59.2	114
464	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , <b>2019</b> , 33, 379-389	10.7	287

463	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , <b>2019</b> , 9, 370-383	24.4	228
462	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. <i>Nature Communications</i> , <b>2019</b> , 10, 244	17.4	63
461	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 1	22.4	119
460	The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. <i>Cancer</i> , <b>2019</b> , 125, 1470-1481	6.4	132
459	Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 46-54	7.1	17
458	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 595-598	4.5	14
457	New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2019</b> , 27, 33-39	1.9	
456	Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 346-357	7.1	61
455	Treatment-free remission in chronic myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , <b>2019</b> , 17, 686-696	0.6	4
454	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. <i>International Journal of Hematology</i> , <b>2018</b> , 107, 689-695	2.3	7
453	Disruption of Wnt/ECatenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in -Mutant Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2417-2429	12.9	38
452	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2294-2303	12.9	75
451	Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , <b>2018</b> , 124, 1160-1168	6.4	14
450	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , <b>2018</b> , 18, 359	4.8	11
449	Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , <b>2018</b> , 124, 2740-2747	6.4	32
448	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. <i>Lancet Haematology</i> , <b>2018</b> , 5, e136-e146	14.6	28
447	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , <b>2018</b> , 132, 393-404	2.2	221
446	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 84-90	7.1	23



445	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1312-1322	1.9	9
444	Acute myeloid leukaemia. <i>Lancet, The</i> , <b>2018</b> , 392, 593-606	4.0	280
443	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1301-1310	7.1	75
442	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1136-1141	7.1	54
441	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial. <i>Blood</i> , <b>2018</b> , 132, 3005-3005	2.2	6
440	Pregnancy Outcomes in Patients Treated with Bosutinib. <i>Blood</i> , <b>2018</b> , 132, 1729-1729	2.2	6
439	Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 2733-2733	2.2	3
438	Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. <i>Blood</i> , <b>2018</b> , 132, 790-790	2.2	10
437	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , <b>2018</b> , 132, 465-465	2.2	34
436	Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7002-7002	2.2	11
435	Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS7073-TPS7073	2.2	4
434	Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. <i>Cancer</i> , <b>2018</b> , 124, 587-595	6.4	14
433	Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 213-221	7.1	59
432	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2684-2692	2.2	446
431	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 231-237	2.2	220
430	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 143	22.4	32
429	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology,the</i> , <b>2018</b> , 5, e618-e627	14.6	105
428	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. <i>Cancer Medicine</i> , <b>2018</b> , 7, 5457-5469	4.8	17

427	A second-generation TKI should always be used as initial therapy for CML. <i>Blood Advances</i> , <b>2018</b> , 2, 3653-3655	8	8
426	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1425-1433	8.7	35
425	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. <i>Haematologica</i> , <b>2018</b> , 103, 1298-1307	6.6	30
424	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 889-903	21.7	145
423	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 767-775	4.7	27
422	Reply to K.R. Hoffman. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 567-568	2.2	3
421	Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1-6	1.9	4
420	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1061-1075	21.7	305
419	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 684-695.e6	2	25
418	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. <i>Cancer</i> , <b>2017</b> , 123, 2875-2880	6.4	57
417	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. <i>Cancer</i> , <b>2017</b> , 123, 3050-3060	6.4	39
416	Treatment of Relapsed/Refractory Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , <b>2017</b> , 18, 17	5.4	124
415	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. <i>Blood</i> , <b>2017</b> , 129, 572-581	2.2	191
414	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. <i>Haematologica</i> , <b>2017</b> , 102, 519-528	6.6	16
413	Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. <i>Blood</i> , <b>2017</b> , 130, 2084-2091	2.2	33
412	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 897-901	2	101
411	A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. <i>Scientific Reports</i> , <b>2017</b> , 7, 11253	4.9	35
410	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , <b>2017</b> , 123, 4430-4439	6.4	30

409	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , <b>2017</b> , 123, 4391-4402	6.4	76
408	First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1214-1223	7.1	27
407	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1303-1313	3	12
406	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. <i>Cancer</i> , <b>2017</b> , 123, 609-616	6.4	3
405	Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 722-725	1.9	3
404	Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). <i>American Journal of Hematology</i> , <b>2017</b> , 92, E3-E4	7.1	13
403	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , <b>2017</b> , 123, 459-467	6.4	39
402	Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 78-82	2	43
401	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , <b>2017</b> , 1, 1312-1323	7.8	55
400	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	22
399	Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7002-7002	2.2	5
398	Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7012-7012	2.2	6
397	Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7051-7051	2.2	9
396	Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 237-9	1.9	21
395	Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , <b>2016</b> , 122, 3650-3656	6.4	105
394	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , <b>2016</b> , 122, 3336-3343	6.4	11
393	Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1206-1214	7.1	55
392	Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. <i>Lancet Haematology,the</i> , <b>2016</b> , 3, e581-e591	14.6	30

391	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. <i>Haematologica</i> , <b>2016</b> , 101, e324-7	6.6	4
390	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 355ra117	17.5	93
389	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2333-40	2.2	485
388	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. <i>Cancer</i> , <b>2016</b> , 122, 238-48	6.4	24
387	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 392-400	4.5	79
386	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 114-26	4.5	12
385	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 163-8.e1-2	2	15
384	Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 213-222.e2	2	21
383	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 152-62	2	17
382	Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 1921-1921	2.2	4
381	CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. <i>Blood</i> , <b>2016</b> , 128, 1923-1923	2.2	1
380	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. <i>Blood</i> , <b>2016</b> , 128, 3171-3171	2.2	2
379	Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. <i>Blood</i> , <b>2016</b> , 128, 625-625	2.2	12
378	Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 606-16	7.1	61
377	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). <i>American Journal of Hematology</i> , <b>2016</b> , 91, 227-32	7.1	29
376	Chronic Myeloid Leukemia <b>2016</b> , 1-11		2
375	Chronic myeloid leukemia: sequencing of TKI therapies. <i>Hematology American Society of Hematology Education Program</i> , <b>2016</b> , 2016, 164-169	3.1	9
374	Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 286-96	2	27

373	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 612-21	21.7	164
372	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1864-71	2.2	46
371	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , <b>2016</b> , 101, 541-58	6.6	61
370	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , <b>2016</b> , 127, 1269-75	2.2	87
369	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Blood</i> , <b>2016</b> , 127, 2742-50	2.2	97
368	Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 869-74	7.1	98
367	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. <i>Leukemia Research</i> , <b>2016</b> , 48, 84-91	2.7	88
366	Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 97-110	4.5	33
365	Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. <i>Cancer</i> , <b>2015</b> , 121, 1637-44	6.4	37
364	Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 27-30	7.1	28
363	Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 120-7	1.9	25
362	Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2015</b> , 87, 346-56	4.6	65
361	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology,the</i> , <b>2015</b> , 2, e186-93	14.6	153
360	Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. <i>Journal of Infection and Chemotherapy</i> , <b>2015</b> , 21, 663-7	2.2	2
359	Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. <i>Cancer</i> , <b>2015</b> , 121, 234-42	6.4	123
358	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology,the</i> , <b>2015</b> , 2, e118-28	14.6	52
357	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , <b>2015</b> , 125, 3236-45	2.4	90
356	Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 32	22.4	22



355	Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 1440-54	54	56
354	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1547-1555	21.7	188
353	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology, the</i> , <b>2015</b> , 2, e376-83	14.6	71
352	Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. <i>Leukemia Research</i> , <b>2015</b> , 39, 822-7	2.7	15
351	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <i>Leukemia Research</i> , <b>2015</b> , 39, 1367-74	2.7	35
350	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 69-81	4.5	136
349	New treatment for acute myelogenous leukemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 95-106	4	21
348	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. <i>Lancet Haematology, the</i> , <b>2015</b> , 2, e339-46	14.6	86
347	A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. <i>Haematologica</i> , <b>2015</b> , 100, 898-904	6.6	43
346	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 276-81 <sup>1</sup>	7.1	114
345	Targeted Therapies in Chronic Myeloid Leukemia <b>2015</b> , 111-120		
344	Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. <i>Blood</i> , <b>2015</b> , 126, 1699-706	2.2	42
343	Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. <i>Blood</i> , <b>2015</b> , 126, 222-32	2.2	79
342	Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. <i>Haematologica</i> , <b>2015</b> , 100, e494-5	6.6	13
341	Effect of treatment with a JAK2-selective inhibitor, Fedratinib, on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 294	8.5	32
340	The impact of dasatinib on pregnancy outcomes. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 1111-5	7.1	74
339	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 1065-70	7.1	16
338	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 471-7	4.5	26



337	Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Cancer</i> , <b>2015</b> , 121, 3894-904	6.4	47
336	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 769-73	7.1	20
335	Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 755-68	7.1	58
334	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 552-8	4.7	9
333	Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. <i>Expert Opinion on Drug Delivery</i> , <b>2015</b> , 12, 1107-20	8	20
332	Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. <i>American Journal of Hematology</i> , <b>2015</b> , 90, E66-72	7.1	42
331	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2546-2546	2.2	12
330	Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 7047-7047 <sup>2</sup>		5
329	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. <i>Oncotarget</i> , <b>2015</b> , 6, 30487-99	3.3	28
328	Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 155-162.e1	2	35
327	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , <b>2014</b> , 120, 373-80	6.4	43
326	Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1451-62	1.9	28
325	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , <b>2014</b> , 23, 943-54	5.9	25
324	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. <i>Blood</i> , <b>2014</b> , 123, 1309-18	2.2	102
323	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , <b>2014</b> , 123, 494-500	2.2	309
322	BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. <i>Cancer Cell</i> , <b>2014</b> , 26, 428-442	24.3	233
321	Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. <i>Cancer</i> , <b>2014</b> , 120, 2142-9	6.4	88
320	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. <i>Blood Reviews</i> , <b>2014</b> , 28, 179-87	11.1	30

319	Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 947-53	7.1	76
318	Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). <i>Cancer</i> , <b>2014</b> , 120, 3660-8	6.4	69
317	Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1735-40	12.9	67
316	Numb chin syndrome by precursor B acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 860-1	7.1	6
315	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 89-97	4.7	99
314	Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1390-8	4.7	14
313	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. <i>Blood</i> , <b>2014</b> , 123, 94-100	2.2	175
312	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i> , <b>2014</b> , 123, 2317-24	2.2	137
311	Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3077	2.2	15
310	Ponatinib in Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 577	59.2	18
309	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. <i>Haematologica</i> , <b>2014</b> , 99, 465-73	6.6	137
308	Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , <b>2014</b> , 23, 265-72	5.9	9
307	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 732-42	7.1	83
306	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2879-86	1.9	25
305	A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 223-30	2	29
304	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. <i>Blood</i> , <b>2014</b> , 124, 3135-3135		35
303	Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7027-7027	2.2	15
302	Chronic Myeloid Leukemia <b>2014</b> , 1944-1957.e2		1

301	Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 530-3	2	66
300	Chronic myeloid leukemia: overview of new agents and comparative analysis. <i>Current Treatment Options in Oncology</i> , <b>2013</b> , 14, 127-43	5.4	32
299	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1599-607	3.5	21
298	Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1977-86	4	7
297	Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 1024-9	7.1	55
296	Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 584-91	2	42
295	Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 515-29	2.9	69
294	Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1411-7	1.9	79
293	Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 1433-52	3.5	18
292	Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 693-9	2	6
291	Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 354-62	21.7	33
290	Current practices in the management of chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 48-54	2	8
289	Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 477-84	2	19
288	The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 302-6	2	18
287	Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , <b>2013</b> , 1, 607-623	1.1	
286	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , <b>2013</b> , 122, 872-84	2.2	1413
285	Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. <i>Clinical Investigation</i> , <b>2013</b> , 3, 1127-1138		3
284	Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 659-66	4.5	19

283	A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. <i>European Journal of Cancer Care</i> , <b>2013</b> , 22, 605-11	2.4	10
282	Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3681-7	2.2	278
281	The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. <i>Haematologica</i> , <b>2013</b> , 98, e131	6.6	7
280	Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. <i>Haematologica</i> , <b>2013</b> , 98, e141-2	6.6	5
279	Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. <i>Blood</i> , <b>2013</b> , 122, 641-7	2.2	72
278	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , <b>2013</b> , 121, 4655-62	2.2	296
277	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , <b>2013</b> , 121, 4867-74	2.2	110
276	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. <i>Blood</i> , <b>2013</b> , 122, 2807-11; quiz 2920	2.2	42
275	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. <i>Haematologica</i> , <b>2013</b> , 98, 1686-8	6.6	22
274	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. <i>Cancer</i> , <b>2012</b> , 118, 418-27	6.4	21
273	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , <b>2012</b> , 119, 1981-7	2.2	249
272	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. <i>Blood</i> , <b>2012</b> , 119, 4524-6	2.2	49
271	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. <i>Blood</i> , <b>2012</b> , 119, 3403-12	2.2	242
270	How I treat newly diagnosed chronic phase CML. <i>Blood</i> , <b>2012</b> , 120, 1390-7	2.2	88
269	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. <i>Blood</i> , <b>2012</b> , 120, 2573-80	2.2	100
268	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 120, 4840-5	2.2	169
267	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. <i>Haematologica</i> , <b>2012</b> , 97, 731-8	6.6	76
266	Ponatinib in refractory Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2075-88	59.2	556

265	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3486-92	2.2	334
264	Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2381-95	4	8
263	Molecular resistance: an early indicator for treatment change?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 79-87	2	3
262	Nilotinib-associated vascular events. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 337-40	2	99
261	Chronic myeloid leukemia: the race is yet to be won. <i>Cmaj</i> , <b>2012</b> , 184, 857-8	3.5	
260	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. <i>Cancer</i> , <b>2012</b> , 118, 2665-73	6.4	36
259	Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Cancer</i> , <b>2012</b> , 118, 3123-7	6.4	187
258	Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. <i>Cancer</i> , <b>2012</b> , 118, 5283-92	6.4	27
257	Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. <i>Cancer</i> , <b>2012</b> , 118, 5811-8	6.4	53
256	Treatment options for chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 815-28	4	12
255	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , <b>2012</b> , 119, 1123-9	2.2	435
254	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2204-10	2.2	132
253	Molecular targeted therapy in acute myeloid leukemia. <i>Hematology</i> , <b>2012</b> , 17 Suppl 1, S59-62	2.2	24
252	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. <i>Haematologica</i> , <b>2012</b> , 97, 1029-35	6.6	62
251	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial. <i>Blood</i> , <b>2012</b> , 120, 915-915	2.2	6
250	Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. <i>Clinical Advances in Hematology and Oncology</i> , <b>2012</b> , 10, 1-16	0.6	1
249	The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 421-6	2	12
248	Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 524-31	2.2	70

247	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , <b>2011</b> , 117, 1141-5	2.2	296
246	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. <i>Blood</i> , <b>2011</b> , 117, 1822-7	2.2	54
245	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. <i>Blood</i> , <b>2011</b> , 117, 3641-7	2.2	51
244	Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. <i>Blood</i> , <b>2011</b> , 117, 5600-6	2.2	49
243	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Blood</i> , <b>2011</b> , 118, 4541-6; quiz 4759	2.2	115
242	Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. <i>Blood</i> , <b>2011</b> , 118, 4353-8	2.2	73
241	Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 396-409	15.9	555
240	Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4260-5	2.2	63
239	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. <i>Cancer</i> , <b>2011</b> , 117, 572-80	6.4	41
238	Monitoring molecular response in chronic myeloid leukemia. <i>Cancer</i> , <b>2011</b> , 117, 1113-22	6.4	17
237	Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. <i>Cancer</i> , <b>2011</b> , 117, 982-91	6.4	11
236	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , <b>2011</b> , 117, 1236-44	6.4	30
235	Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. <i>Cancer</i> , <b>2011</b> , 117, 327-35	6.4	17
234	Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. <i>Cancer</i> , <b>2011</b> , 117, 897-906	6.4	46
233	Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. <i>Cancer</i> , <b>2011</b> , 117, 2145-55	6.4	81
232	FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?. <i>Cancer</i> , <b>2011</b> , 117, 3293-304	6.4	42
231	Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. <i>Cancer</i> , <b>2011</b> , 117, 4869-4877	6.4	44
230	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. <i>Cancer</i> , <b>2011</b> , 117, 5085-93	6.4	12



229	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. <i>Haematologica</i> , <b>2011</b> , 96, 62-8	6.6	150
228	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 1010-6	1.9	5
227	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. <i>Blood</i> , <b>2011</b> , 118, 4567-76	2.2	345
226	Evolution of therapies for chronic myelogenous leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2011</b> , 17, 465-76	2.6	37
225	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4417-23	2.2	230
224	Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy,. <i>Blood</i> , <b>2011</b> , 118, 3771-3771	2.2	4
223	Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),. <i>Blood</i> , <b>2011</b> , 118, 3785-3785	2.2	3
222	The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2011</b> , 33, 455-60		1
221	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. <i>Cancer Science</i> , <b>2010</b> , 101, 2005-10	6.9	11
220	Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 303-12	4.5	34
219	Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4207-13	2.2	138
218	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3880-9	2.2	299
217	Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 392-7	2.2	204
216	Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 778-82	1.9	44
215	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1856-62	2.2	298
214	Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 398-404	2.2	198
213	Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 424-30	2.2	235
212	Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2010</b> , 10 Suppl 1, S14-9	2	

211	Third-generation tyrosine kinase inhibitors and beyond. <i>Seminars in Hematology</i> , <b>2010</b> , 47, 371-80	4	17
210	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 1478-84	1.9	4
209	Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. <i>Core Evidence</i> , <b>2010</b> , 4, 207-13	4.9	23
208	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 116, 4422-9	2.2	280
207	Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 2260-70	59.2	1197
206	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?. <i>Current Oncology Reports</i> , <b>2010</b> , 12, 302-13	6.3	24
205	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , <b>2010</b> , 116, 1419-30	6.4	35
204	Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. <i>Cancer</i> , <b>2010</b> , 116, 2673-81	6.4	42
203	Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. <i>Cancer</i> , <b>2010</b> , 116, 3152-9	6.4	15
202	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. <i>Cancer</i> , <b>2010</b> , 116, 3631-7	6.4	20
201	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. <i>Cancer</i> , <b>2010</b> , 116, 3852-61	6.4	96
200	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. <i>Cancer</i> , <b>2010</b> , 116, 3830-4	6.4	195
199	Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). <i>Cancer</i> , <b>2010</b> , 116, 4991-5000	6.4	19
198	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. <i>Cancer</i> , <b>2010</b> , 116, 5568-74	6.4	88
197	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. <i>Leukemia Research</i> , <b>2010</b> , 34, 752-6	2.7	85
196	Chronic Myeloid Leukemia: Pathophysiology and Therapeutics <b>2010</b> , 139-153		
195	T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 321-2	1.9	1
194	Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3659-63	2.2	52

193	Imatinib and beyond--exploring the full potential of targeted therapy for CML. <i>Nature Reviews Clinical Oncology</i> , <b>2009</b> , 6, 535-43	19.4	110
192	Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3642-9	2.2	76
191	High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4754-9	2.2	99
190	del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. <i>Cancer Genetics and Cytogenetics</i> , <b>2009</b> , 192, 18-23		5
189	First-line therapy for chronic myeloid leukemia: Past, present, and future. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 287-93	7.1	35
188	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , <b>2009</b> , 115, 551-60	6.4	97
187	Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. <i>Cancer</i> , <b>2009</b> , 115, 1381-94	6.4	40
186	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. <i>Cancer</i> , <b>2009</b> , 115, 2482-90	6.4	98
185	Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. <i>Cancer</i> , <b>2009</b> , 115, 2912-21	6.4	47
184	Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. <i>Cancer</i> , <b>2009</b> , 115, 3217-21	6.4	61
183	Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. <i>Cancer</i> , <b>2009</b> , 115, 3709-18	6.4	86
182	Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. <i>Cancer</i> , <b>2009</b> , 115, 3935-43	6.4	33
181	Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. <i>Cancer</i> , <b>2009</b> , 115, 3924-34	6.4	50
180	Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. <i>Cancer</i> , <b>2009</b> , 115, 5382-93	6.4	102
179	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?. <i>Current Oncology Reports</i> , <b>2009</b> , 11, 337-45	6.3	9
178	Treatment selection after imatinib resistance in chronic myeloid leukemia. <i>Targeted Oncology</i> , <b>2009</b> , 4, 3-10	5	44
177	The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. <i>Blood</i> , <b>2009</b> , 114, 4361-8	2.2	107
176	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6041-51	2.2	1019

175	Molecular biology of bcr-abl1-positive chronic myeloid leukemia. <i>Blood</i> , <b>2009</b> , 113, 1619-30	2.2	482
174	Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9 Suppl 3, S261-5		10
173	Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9 Suppl 3, S272-9		7
172	Standard management of patients with chronic myeloid leukemia. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9 Suppl 4, S382-90		4
171	Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?. <i>Mayo Clinic Proceedings</i> , <b>2009</b> , 84, 161-169	6.4	31
170	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. <i>Blood</i> , <b>2009</b> , 113, 2154-60 <sup>2,2</sup>		135
169	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. <i>Blood</i> , <b>2009</b> , 113, 6315-21	2.2	129
168	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. <i>Blood</i> , <b>2009</b> , 113, 3938-46	2.2	144
167	Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. <i>Blood</i> , <b>2009</b> , 113, 6322-9	2.2	137
166	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. <i>Blood</i> , <b>2009</b> , 114, 2037-43	2.2	103
165	AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.. <i>Blood</i> , <b>2009</b> , 114, 636-636	2.2	35
164	Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. <i>Mayo Clinic Proceedings</i> , <b>2009</b> , 84, 161-9	6.4	13
163	Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. <i>Seminars in Oncology</i> , <b>2008</b> , 35, S1-17; quiz S18-20	5.5	21
162	Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. <i>Clinical Lymphoma and Myeloma</i> , <b>2008</b> , 8 Suppl 3, S75-81		1
161	Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Clinical Lymphoma and Myeloma</i> , <b>2008</b> , 8 Suppl 3, S82-8		18
160	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 1127-36	5.9	11
159	Homoharringtonine for the treatment of chronic myelogenous leukemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 1029-37	4	30
158	Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. <i>Future Oncology</i> , <b>2008</b> , 4, 611-21	3.6	21

157	Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4392-9	12.9	83
156	Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 509-14	12.9	19
155	Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1399-402	1.9	23
154	Targeted therapy in chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 99-110	3.5	32
153	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 184-98	9.7	295
152	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. <i>Blood</i> , <b>2008</b> , 111, 1039-43	2.2	175
151	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. <i>Blood</i> , <b>2008</b> , 111, 1774-80	2.2	112
150	The effects of imatinib on pregnancy outcome. <i>Blood</i> , <b>2008</b> , 111, 5505-8	2.2	256
149	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. <i>Blood</i> , <b>2008</b> , 112, 53-5	2.2	111
148	Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. <i>Blood</i> , <b>2008</b> , 112, 516-8	2.2	88
147	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. <i>Blood</i> , <b>2008</b> , 112, 5190-2	2.2	28
146	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , <b>2008</b> , 112, 4839-42	2.2	68
145	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. <i>Cancer</i> , <b>2008</b> , 112, 837-45	6.4	91
144	Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. <i>Cancer</i> , <b>2008</b> , 112, 2112-8	6.4	37
143	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. <i>Cancer</i> , <b>2008</b> , 113, 1933-52	6.4	74
142	Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. <i>Cancer</i> , <b>2008</b> , 113, 985-94	6.4	103
141	The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , <b>2008</b> , 113, 1338-43	6.4	13
140	Targeted Therapy in Myelodysplastic Syndrome <b>2008</b> , 237-260		

139 Targeted Therapy in Chronic Myeloid Leukemia **2008**, 87-99

138	Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2008</b> , 6 Suppl 2, S22-S30	7.3	5
137	Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 547-57	5.9	7
136	Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 7 Suppl 2, S51-7		2
135	Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 7 Suppl 3, S105-12		22
134	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. <i>Cancer</i> , <b>2007</b> , 109, 248-55	6.4	108
133	Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. <i>Cancer</i> , <b>2007</b> , 109, 899-906	6.4	115
132	Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. <i>Cancer</i> , <b>2007</b> , 109, 907-14	6.4	43
131	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. <i>Cancer</i> , <b>2007</b> , 109, 1133-7	6.4	158
130	Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. <i>Cancer</i> , <b>2007</b> , 109, 1355-9	6.4	72
129	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. <i>Cancer</i> , <b>2007</b> , 109, 1556-60	6.4	75
128	Current and emerging treatment options in chronic myeloid leukemia. <i>Cancer</i> , <b>2007</b> , 109, 2171-81	6.4	101
127	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. <i>Cancer</i> , <b>2007</b> , 110, 340-4	6.4	57
126	Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. <i>Cancer</i> , <b>2007</b> , 110, 1295-302	6.4	46
125	Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. <i>Cancer</i> , <b>2007</b> , 110, 2000-6	6.4	38
124	The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2007</b> , 136, 624-7	4.5	187
123	Clinical activity of tipifarnib in hematologic malignancies. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 381-92	5.9	9
122	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 283-9	1.9	40



121	Important therapeutic targets in chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1089-97	2.7	78
120	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Blood</i> , <b>2007</b> , 109, 52-7	2.2	577
119	Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. <i>Haematologica</i> , <b>2007</b> , 92, 170-5	6.6	17
118	Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Current Opinion in Internal Medicine</i> , <b>2007</b> , 14, 138-44		1
117	New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. <i>Seminars in Hematology</i> , <b>2007</b> , 44, S25-31	4	23
116	The biology of chronic myelogenous leukemia: implications for imatinib therapy. <i>Seminars in Hematology</i> , <b>2007</b> , 44, S4-14	4	33
115	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , <b>2007</b> , 109, 3207-13	2.2	354
114	Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , <b>2007</b> , 110, 2991-5	2.2	114
113	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. <i>Blood</i> , <b>2007</b> , 110, 4005-11	2.2	247
112	Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 679-87	5.9	28
111	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.. <i>Blood</i> , <b>2007</b> , 110, 283-283	2.2	6
110	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. <i>Blood</i> , <b>2007</b> , 110, 577-577	2.2	5
109	New Therapies for Chronic Myeloid Leukemia <b>2007</b> , 165-184		
108	The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. <i>Targeted Oncology</i> , <b>2006</b> , 1, 186-196	5	10
107	Keeping up with rapid change. <i>Current Hematologic Malignancy Reports</i> , <b>2006</b> , 1, 1-1	4.4	
106	Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. <i>Cancer</i> , <b>2006</b> , 106, 346-52	6.4	60
105	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. <i>Cancer</i> , <b>2006</b> , 106, 1090-8	6.4	478
104	Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. <i>Cancer</i> , <b>2006</b> , 106, 1306-15	6.4	78

103	Thalidomide therapy for myelofibrosis with myeloid metaplasia. <i>Cancer</i> , <b>2006</b> , 106, 1974-84	6.4	80
102	The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. <i>Cancer</i> , <b>2006</b> , 107, 1918-29	6.4	88
101	Advances in the therapy of chronic idiopathic myelofibrosis. <i>Oncologist</i> , <b>2006</b> , 11, 929-43	5.7	22
100	Pregnancy among patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1204-8	2.2	183
99	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 2531-41	59.2	1414
98	Chronic myeloid leukemia: diagnosis and treatment. <i>Mayo Clinic Proceedings</i> , <b>2006</b> , 81, 973-88	6.4	140
97	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , <b>2006</b> , 108, 28-37	2.2	977
96	Optimal Therapy for Chronic Myeloid Leukemia Blast Crisis: Current Concepts. <i>Clinical Leukemia</i> , <b>2006</b> , 1, 87-94		
95	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , <b>2006</b> , 108, 1809-20	2.2	998
94	Dasatinib: A Dual ABL and SRC Inhibitor <b>2006</b> , 59-68		
93	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. <i>Blood</i> , <b>2006</b> , 107, 480-2	2.2	53
92	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , <b>2006</b> , 108, 1421-3	2.2	77
91	Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. <i>Blood</i> , <b>2006</b> , 108, 1835-40	2.2	181
90	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , <b>2006</b> , 108, 1497-503	2.2	287
89	Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. <i>Blood</i> , <b>2006</b> , 108, 2811-3	2.2	130
88	Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. <i>Current Opinion in Oncology</i> , <b>2006</b> , 18, 578-83	4.2	21
87	Overcoming drug resistance in chronic myeloid leukemia. <i>Current Opinion in Hematology</i> , <b>2006</b> , 13, 79-86	3.3	16
86	Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 2542-51	59.2	1133

85	New strategies in chronic myeloid leukemia. <i>International Journal of Hematology</i> , <b>2006</b> , 83, 289-93	2.3	20
84	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. <i>Mayo Clinic Proceedings</i> , <b>2005</b> , 80, 390-402	6.4	46
83	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. <i>Blood</i> , <b>2005</b> , 105, 2281-6	2.2	92
82	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. <i>Leukemia Research</i> , <b>2005</b> , 29, 649-52	2.7	17
81	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. <i>Cancer</i> , <b>2005</b> , 103, 2099-108	6.4	57
80	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. <i>Cancer</i> , <b>2005</b> , 104, 777-80	6.4	22
79	Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. <i>Current Molecular Medicine</i> , <b>2005</b> , 5, 615-23	2.5	28
78	Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2805-12	2.2	44
77	Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3948-56	2.2	259
76	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3425-32	12.9	237
75	New targeted approaches in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6316-24	2.2	45
74	AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).. <i>Blood</i> , <b>2005</b> , 106, 37-37	2.2	9
73	Investigational agents in myeloid disorders. <i>Advances in Pharmacology</i> , <b>2004</b> , 51, 59-97	5.7	
72	Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 68-75	12.9	49
71	Phase I study of bortezomib in refractory or relapsed acute leukemias. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 3371-6	12.9	179
70	Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1287-92	2.2	124
69	Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. <i>British Journal of Haematology</i> , <b>2004</b> , 124, 727-38	4.5	6
68	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. <i>British Journal of Haematology</i> , <b>2004</b> , 125, 187-95	4.5	70

67	Imatinib mesylate in the treatment of chronic myelogenous leukemia. <i>International Journal of Hematology</i> , <b>2004</b> , 79, 411-9	2.3	12
66	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , <b>2004</b> , 100, 116-21	6.4	97
65	New agents in acute myeloid leukemia and other myeloid disorders. <i>Cancer</i> , <b>2004</b> , 100, 441-54	6.4	34
64	Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. <i>Cancer</i> , <b>2004</b> , 100, 2064-78	6.4	22
63	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. <i>Cancer</i> , <b>2004</b> , 100, 2592-7	6.4	53
62	Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , <b>2004</b> , 100, 2396-402	6.4	32
61	Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Cancer</i> , <b>2004</b> , 101, 2788-801	6.4	461
60	Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 2187-95	1.9	30
59	Natural history and staging of chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , <b>2004</b> , 18, 569-84, viii	3.1	65
58	Investigational strategies in chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , <b>2004</b> , 18, 619-39, ix	3.1	6
57	Clonal evolution in chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , <b>2004</b> , 18, 671-84, x	3.1	67
56	Accelerated and blastic phases of chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , <b>2004</b> , 18, 753-74, xii	3.1	29
55	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. <i>Blood</i> , <b>2004</b> , 103, 2873-8	2.2	344
54	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i> , <b>2004</b> , 103, 4396-407	2.2	458
53	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. <i>Blood</i> , <b>2004</b> , 104, 1979-88	2.2	144
52	Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for Chronic Myelogenous Leukemia (CML). <i>Blood</i> , <b>2004</b> , 104, 812-812	2.2	2
51	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. <i>Blood</i> , <b>2003</b> , 101, 473-5	2.2	273
50	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. <i>Blood</i> , <b>2003</b> , 101, 1692-7	2.2	193

49	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. <i>Blood</i> , <b>2003</b> , 101, 3794-800	2.2	183
48	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. <i>Blood</i> , <b>2003</b> , 102, 4527-34	2.2	117
47	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. <i>Blood</i> , <b>2003</b> , 102, 83-6	2.2	164
46	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. <i>Blood</i> , <b>2003</b> , 101, 97-100	2.2	128
45	A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. <i>Cancer</i> , <b>2003</b> , 97, 1234-41	6.4	43
44	Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. <i>Cancer</i> , <b>2003</b> , 97, 1033-41	6.4	190
43	Use of arsenic trioxide (As <sub>2</sub> O <sub>3</sub> ) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. <i>Cancer</i> , <b>2003</b> , 97, 2218-24	6.4	106
42	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , <b>2003</b> , 97, 2225-8	6.4	21
41	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. <i>Cancer</i> , <b>2003</b> , 97, 2760-8	6.4	96
40	Chronic myelogenous leukemia: a review and update of therapeutic strategies. <i>Cancer</i> , <b>2003</b> , 98, 437-57	6.4	61
39	Results of decitabine (5-aza-2'-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. <i>Cancer</i> , <b>2003</b> , 98, 522-8	6.4	200
38	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. <i>Cancer</i> , <b>2003</b> , 98, 888-93	6.4	62
37	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , <b>2003</b> , 98, 1905-11	6.4	114
36	Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Clinical Lymphoma and Myeloma</i> , <b>2003</b> , 4 Suppl 1, S30-5		15
35	Advanced-phase chronic myeloid leukemia. <i>Seminars in Hematology</i> , <b>2003</b> , 40, 79-86	4	37
34	Comments on the Hammersmith policy. <i>Seminars in Hematology</i> , <b>2003</b> , 40, 105-106	4	
33	Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. <i>Blood</i> , <b>2003</b> , 101, 4714-6	2.2	132
32	New agents in chronic myelogenous leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2003</b> , 1, 501-12	7.3	

31	Advanced-phase chronic myeloid leukemia. <i>Seminars in Hematology</i> , <b>2003</b> , 40, 79-86	4	37
30	CMML: a biologically distinct myeloproliferative disease. <i>Psychophysiology</i> , <b>2003</b> , 2, 202-8		11
29	Central nervous system relapse in adults with acute lymphoblastic leukemia. <i>Cancer</i> , <b>2002</b> , 94, 773-9	6.4	67
28	Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. <i>Cancer</i> , <b>2002</b> , 94, 1492-9	6.4	123
27	Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. <i>Cancer</i> , <b>2002</b> , 94, 2024-32	6.4	58
26	Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. <i>Leukemia Research</i> , <b>2002</b> , 26, 881-4	2.7	104
25	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. <i>Blood</i> , <b>2002</b> , 99, 3547-53	2.2	251
24	Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. <i>Blood</i> , <b>2002</b> , 99, 2265-7	2.2	73
23	Leukemia cells eat their VEGF tables. <i>Blood</i> , <b>2002</b> , 100, 4256-4256	2.2	23
22	Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. <i>Seminars in Hematology</i> , <b>2002</b> , 39, 26-30	4	16
21	Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2167-76	12.9	72
20	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2177-87	12.9	84
19	High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. <i>Cancer</i> , <b>2001</b> , 92, 7-14	6.4	42
18	High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. <i>Cancer</i> , <b>2001</b> , 92, 1999-2015	6.4	70
17	Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. <i>Cancer</i> , <b>2001</b> , 92, 2016-22	6.4	32
16	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. <i>Cancer</i> , <b>2001</b> , 92, 2501-7	6.4	19
15	Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 547-61	2.2	616
14	Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3513-21	2.2	73



13	Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 284-92	2.2	126
12	Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin □ All-Trans Retinoic Acid □ Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , <b>1999</b> , 93, 2478-2484	2.2	183
11	Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance. <i>Blood</i> , <b>1999</b> , 93, 2075-2080	2.2	65
10	Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage Therapy. <i>Blood</i> , <b>1999</b> , 93, 3149-3150	2.2	18
9	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. <i>Investigational New Drugs</i> , <b>1999</b> , 17, 89-95	4.3	28
8	Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. <i>Cancer</i> , <b>1999</b> , 86, 2632-41	6.4	143
7	Thiotepa for the treatment of thrombocytopenia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. <i>Cancer</i> , <b>1997</b> , 80, 396-400	6.4	1
6	Chronic myelogenous leukemia: a review. <i>American Journal of Medicine</i> , <b>1996</b> , 100, 555-70	2.4	123
5	Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. <i>Leukemia and Lymphoma</i> , <b>1996</b> , 21, 85-92	1.9	31
4	Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. <i>Cancer</i> , <b>1995</b> , 75, 464-70	6.4	47
3	Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. <i>Cancer</i> , <b>1995</b> , 76, 2393-417	6.4	110
2	All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. <i>Cancer</i> , <b>1994</b> , 73, 2946-52	6.4	40
1	Standard Management of Patients with Chronic Myeloid Leukemia71-85		